ArticleBMJ case reports2026
Aggressive phenotype of multiple sclerosis, characterised by atypical initial symptoms and a fulminant clinical progression.
Article in BMJ case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A previously healthy male in his late 40s presented with progressively worsening neurological symptoms-tetraparesis, visual disturbances, aphasia and dysphagia. Brain MRI revealed multiple large contrast-enhancing lesions with mass effect. After extensive investigation, a demyelinating central nervous system (CNS) disease was suspected; however, a differential diagnosis with primary CNS vasculitis was also considered. Despite treatment with high-dose corticosteroids, plasma exchange and immunoglobulins, the patient's neurological condition continued to deteriorate. A brain biopsy confirmed an active demyelinating process. A diagnosis of aggressive multiple sclerosis was established. Immunotherapy with ocrelizumab resulted in clinical stabilisation. This case highlights the diagnostic challenges of atypical demyelinating presentations and the critical role of brain biopsy in guiding early treatment in fulminant cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.